C19-IG 20% / Grifols - LARVOL DELTA

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial. (PubMed, EClinicalMedicine) - P3 | "Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Grifols."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients (clinicaltrials.gov) - P3 | N=465 | Terminated | Sponsor: Grifols Therapeutics LLC | N=801 ➔ 465 | Recruiting ➔ Terminated; Study Stopped for Futility

Enrollment change • Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients (clinicaltrials.gov) - P3; N=801; Recruiting; Sponsor: Grifols Therapeutics LLC; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR

A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients (clinicaltrials.gov) - P3; N=801; Not yet recruiting; Sponsor: Grifols Therapeutics LLC

New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR